
|Videos|December 2, 2022
Dr. Laura Sena discusses bipolar androgen therapy for prostate cancer
Author(s)Urology Times staff
“This is different from other standard-of-care therapies for prostate cancer because usually we are inhibiting androgen receptor (AR) activity and here we’re actually stimulating AR,” explained Laura Anne Sena, MD, PhD.
Advertisement
In an interview during the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












